The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a rare and life-threatening genetic condition causing an inborn error in metabolism. This was shown in a clinical study recently published by an international research team led by Professor Dr Günter Schwarz from the Institute of Biochemistry at the University of Cologne. MoCD type A is a very rare disease. It affects around one…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply